ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous …
Analyst Charles Duncan of Piper Jaffray came away with an increased confidence in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after attending an investor meeting with management.
After an investors meeting in New York City this week with ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) touching base about its upcoming commercial launch for Nuplazid, …
Needham analyst Alan Carr was out today with a favorable report on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after meeting with management for a corporate update and hosting a series of …
Healthcare analysts are optimistic on both ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Celgene Corporation (NASDAQ:CELG) as ACADIA’s primary commercialized product received positive coverage and …
Analysts weighed in today on biopharmaceutical giants Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in light of recent company updates.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is up 5% in pre-market trading after news that its drug Nuplazid received FDA approval on Friday after market …
With earnings season around the corner, analysts from Cowen & Co. are weighing in with expectations for some of the most notable names …
Healthcare analysts provide insight on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) with differing opinions.
